United Therapeutics Corporation (UTHR)

NASDAQ: UTHR · Real-Time Price · USD
384.52
-6.93 (-1.77%)
Sep 4, 2025, 11:32 AM - Market open
-1.77%
Market Cap17.39B
Revenue (ttm)3.08B
Net Income (ttm)1.24B
Shares Out 45.23M
EPS (ttm)25.63
PE Ratio15.00
Forward PE13.67
Dividendn/a
Ex-Dividend Daten/a
Volume393,810
Open395.60
Previous Close391.45
Day's Range379.39 - 396.54
52-Week Range266.98 - 436.95
Beta0.62
AnalystsStrong Buy
Price Target424.43 (+10.38%)
Earnings DateOct 29, 2025

About UTHR

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitr... [Read more]

Sector Healthcare
IPO Date Jun 17, 1999
Employees 1,305
Stock Exchange NASDAQ
Ticker Symbol UTHR
Full Company Profile

Financial Performance

In 2024, United Therapeutics's revenue was $2.88 billion, an increase of 23.63% compared to the previous year's $2.33 billion. Earnings were $1.20 billion, an increase of 21.35%.

Financial Statements

Analyst Summary

According to 14 analysts, the average rating for UTHR stock is "Strong Buy." The 12-month stock price target is $424.43, which is an increase of 10.38% from the latest price.

Price Target
$424.43
(10.38% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

United Therapeutics: Is UTHR Stock Still A Buy At $400?

United Therapeutics' stock (NASDAQ: UTHR) surged 33% on September 2nd after the company announced positive late-stage clinical trial results for Tyvaso (treprostinil) Inhalation Solution in idiopathic...

1 day ago - Forbes

Why Is United Therapeutics Stock Rallying On Tuesday?

United Therapeutics Corporation UTHR released data on Tuesday from its TETON-2 study evaluating the use of nebulized Tyvaso (treprostinil) Inhalation Solution for idiopathic pulmonary fibrosis (IPF).

2 days ago - Benzinga

United Therapeutics surges as Tyvaso succeeds in IPF trial: should you invest?

Shares of United Therapeutics jumped nearly 40% on Tuesday's opening trade after the company reported its inhaled lung therapy Tyvaso met the main goal in a late-stage study for idiopathic pulmonary f...

2 days ago - Invezz

United Therapeutics shares surge on successful late-stage lung disease study

Shares of United Therapeutics surged over 42% in premarket trading on Tuesday after its lung disease treatment, treprostinil, met the main goal in a late stage study.

2 days ago - Reuters

United Therapeutics Corporation Announces TETON-2 Pivotal Study of Tyvaso® Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary Fibrosis

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its TETON-2 study evaluating the ...

2 days ago - Business Wire

United Therapeutics Corporation to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that James Edgemond, Chief Financial O...

6 days ago - Business Wire

United Therapeutics: Critical September IPF Data Catalyst Sets Up Momentous Year

United Therapeutics Corporation remains a Buy as it robustly defends its PAH franchise, counters competitive threats, and posts strong Q2 results with double-digit growth. Upcoming TETON-2 data for Ty...

8 days ago - Seeking Alpha

United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced that it will enter today into two Accelerate...

4 weeks ago - Business Wire

United Therapeutics Corporation (UTHR) Q2 2025 Earnings Call Transcript

United Therapeutics Corporation (NASDAQ:UTHR) Q2 2025 Earnings Conference Call July 30, 2025 9:00 AM ET Company Participants C.Q. Deng - Corporate Participant Dewey Steadman - Head of Investor Relati...

5 weeks ago - Seeking Alpha

United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced record financial results for the quart...

5 weeks ago - Business Wire

United Therapeutics Corporation to Report Second Quarter 2025 Financial Results Before Market Open on Wednesday, July 30, 2025

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2025 financial results before ...

7 weeks ago - Business Wire

United Therapeutics and Intermountain Health Announce the First Patient Treated With External Liver Support Using a Bioengineered Liver

EDEN PRAIRIE, Minn. & MURRAY, Utah--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, and Intermountain Health, one of the nation's top health systems and ...

2 months ago - Business Wire

United Therapeutics Corporation Concludes Enrollment of the ADVANCE OUTCOMES Study of Ralinepag for the Treatment of Pulmonary Arterial Hypertension

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced the conclusion of enrollment of the phase 3 ...

2 months ago - Business Wire

United Therapeutics: Tanking On Rival's PAH Data - I'd Consider Buying Stock

United Therapeutics Corporation stock was down substantially yesterday as rival Insmed's PAH data blew the market away. Insmed's treprostinil based product seemingly edged United's Tyvaso on key measu...

3 months ago - Seeking Alpha

United Therapeutics Corporation (UTHR) Q1 2025 Earnings Call Transcript

United Therapeutics Corporation (NASDAQ:UTHR) Q1 2025 Earnings Conference Call April 30, 2025 9:00 AM ET Company Participants Dewey Steadman - Head of Investor Relations Martine Rothblatt - Chairpers...

4 months ago - Seeking Alpha

United Therapeutics Corporation Reports First Quarter 2025 Financial Results

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ...

4 months ago - Business Wire

United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2025 International Conference

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent research across its commer...

4 months ago - Business Wire

United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the International Society for Heart and Lung Transplantation 45th Annual Meeting and Scientific Sessions

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that ten posters and presentations acr...

5 months ago - Business Wire

United Therapeutics: Don't Fear The Patent Expiration Too Much

United Therapeutics is rated as a BUY due to high financial growth, positive long-term outlook, and current undervaluation despite patent expiration concerns. The company's revenue is heavily reliant ...

5 months ago - Seeking Alpha

United Therapeutics Corporation to Present at the Leerink Partners Global Healthcare Conference 2025

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that James Edgemond, Chief Financial O...

6 months ago - Business Wire

United Therapeutics Corporation (UTHR) Q4 2024 Earnings Call Transcript

Start Time: 09:00 January 1, 0000 9:31 AM ET United Therapeutics Corporation (NASDAQ:UTHR) Q4 2024 Earnings Conference Call February 26, 2025, 09:00 AM ET Company Participants Martine Rothblatt - Cha...

6 months ago - Seeking Alpha

United Therapeutics Corporation Reports Fourth Quarter and Full Year 2024 Financial Results

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ...

6 months ago - Business Wire

United Therapeutics: A Unique Business With High Margins And Expansion Potential

United Therapeutics is highly undervalued with a P/E of 16x and EV/EBITDA of 8.64x, compared to sector medians of 28x and 15.15x, respectively. The company shows strong revenue growth, driven by Tyvas...

6 months ago - Seeking Alpha

United Therapeutics Corporation to Present at the TD Cowen 45th Annual Health Care Conference

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Michael Benkowitz, President and ...

6 months ago - Business Wire

United Therapeutics Corporation to Report Fourth Quarter and Full Year 2024 Financial Results Before the Market Opens on Wednesday, February 26, 2025

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and full year 2024 financial r...

7 months ago - Business Wire